AGIO

Agios Pharmaceuticals, Inc.

Price Chart

Latest Quote

$28.29

-0.50 (-1.74%)

Current Price

Previous Close	$28.79
Open	$28.95
Day High	$29.39
Day Low	$28.13
Volume	561,244

Fetched: 2026-06-06T06:20:46

Stock Information

Shares Outstanding	59.47M
Total Debt	$35.74M
Cash Equivalents	$737.04M
Revenue	$66.05M
Net Income	$-422.60M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$1.68B
EPS (TTM)	$-7.26
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$981.16M
Sales	$66.05M
Income	$-422.60M
Book/sh	$18.69
Cash/sh	$12.39
Employees	539

Financial Ratios

Quick Ratio	12.80
Current Ratio	14.19
Debt/Eq	3.22

Returns & Margins

ROA	-21.69%
ROE	-32.81%
Operating Margin	-530.34%

Ownership

Insider Ownership	1.09%
Institutional Ownership	108.60%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-6.16
P/S	25.47
P/B	1.51

Analyst Data

Recommendation	buy
Target Price	$40.88

Technical Indicators

SMA20	$28.36
SMA50	$29.48
SMA200	$32.09
RSI	50.54
ATR	1.3371

Shares Float	53.13M
Short Float	12.66%
Short Ratio	5.96
Volatility	0.59
Rel Volume	0.71

Performance History

Week	-3.78%
Month	+4.86%
Quarter	+2.99%
6 Months	+2.91%
YTD	+4.08%
Year	-16.87%
3 Years	+11.91%
5 Years	-49.28%
10 Years	-52.60%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-05	$28.29	561,300
2026-06-04	$28.79	648,200
2026-06-03	$27.68	679,200
2026-06-02	$26.51	1,100,900
2026-06-01	$28.00	853,600
2026-05-29	$29.40	1,432,000
2026-05-28	$30.42	987,600
2026-05-27	$28.62	935,000
2026-05-26	$28.33	903,200
2026-05-22	$28.14	874,500
2026-05-21	$28.79	522,700
2026-05-20	$28.50	678,400
2026-05-19	$27.73	638,000
2026-05-18	$28.21	757,900
2026-05-15	$28.17	604,100
2026-05-14	$28.73	681,900
2026-05-13	$28.77	747,400
2026-05-12	$28.42	766,900
2026-05-11	$27.99	794,300
2026-05-08	$27.79	582,900
2026-05-07	$27.53	722,500
2026-05-06	$26.98	1,083,900

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

📰 Latest News

Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?

Zacks • 2026-06-04T15:30:14Z

How The Tebapivat Setback Is Reframing The Story For Agios Pharmaceuticals (AGIO)

Simply Wall St. • 2026-06-03T13:12:27Z

AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate

Zacks • 2026-06-02T14:24:00Z

Agios Pharmaceuticals licenses global rights to Oscotec's SYK inhibitor cevidoplenib

Proactive • 2026-06-01T16:26:00Z

AGIO Halts Tebapivat Development in Myelodysplastic Syndromes

Zacks • 2026-06-01T13:43:00Z

Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report?

Zacks • 2026-05-29T15:30:08Z

Agios slides after discontinuing development of tebapivat in myelodysplastic syndromes (AGIO)

InvestorsHub • 2026-05-29T14:26:07Z

Exchange-Traded Funds, Equity Futures Rise Pre-Bell Friday Amid US-Iran Deal Hopes

MT Newswires • 2026-05-29T13:16:30Z

Allogene CEO to step down; Agios drug fails key test

BioPharma Dive • 2026-05-29T10:17:00Z

AGIO's Pyrukynd Gets Approval for Thalassemia in Europe

Zacks • 2026-05-25T15:08:00Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Reconciled Cost Of Revenue	$6,345,000	$4,165,000	$2,881,000	$1,704,000
Cost Of Revenue	$6,345,000	$4,165,000	$2,881,000	$1,704,000
Total Revenue	$54,028,000	$36,498,000	$26,823,000	$14,240,000
Operating Revenue	$54,028,000	$36,498,000	$26,823,000	$14,240,000
Expenses
Total Expenses	$526,160,000	$462,235,000	$418,310,000	$403,287,000
Other Income Expense	$1,956,000	$1,095,623,000	$6,055,000	$144,453,000
Other Non Operating Income Expenses	$1,956,000	$6,487,000	$6,055,000	$6,749,000
Net Non Operating Interest Income Expense	$56,379,000	$48,083,000	$33,344,000	$12,793,000
Operating Expense	$519,815,000	$458,070,000	$415,429,000	$401,583,000
Total Other Finance Cost	-	-	-	$-12,793,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-412,781,000	$673,725,000	$-352,088,000	$-231,801,000
Net Interest Income	$56,379,000	$48,083,000	$33,344,000	$12,793,000
Interest Income	$56,379,000	$48,083,000	$33,344,000	$12,793,000
Normalized Income	$-412,781,000	$-348,294,268	$-352,088,000	$-369,505,000
Net Income From Continuing And Discontinued Operation	$-412,781,000	$673,725,000	$-352,088,000	$-231,801,000
Total Operating Income As Reported	$-472,132,000	$-425,737,000	$-391,487,000	$-389,047,000
Net Income Common Stockholders	$-412,781,000	$673,725,000	$-352,088,000	$-231,801,000
Net Income	$-412,781,000	$673,725,000	$-352,088,000	$-231,801,000
Net Income Including Noncontrolling Interests	$-412,781,000	$673,725,000	$-352,088,000	$-231,801,000
Net Income Continuous Operations	$-412,781,000	$673,725,000	$-352,088,000	$-231,801,000
Pretax Income	$-413,797,000	$717,969,000	$-352,088,000	$-231,801,000
Special Income Charges	$0	$1,089,136,000	$0	$137,704,000
Interest Income Non Operating	$56,379,000	$48,083,000	$33,344,000	$12,793,000
Operating Income	$-472,132,000	$-425,737,000	$-391,487,000	$-389,047,000
Gross Profit	$47,683,000	$32,333,000	$23,942,000	$12,536,000
Net Income Discontinuous Operations	-	-	$0	$0
Per Share
Diluted EPS	$-7.12	$11.64	$-6.33	$-4.23
Basic EPS	$-7.12	$11.86	$-6.33	$-4.23
Other
Tax Effect Of Unusual Items	$0	$67,116,732	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-466,955,000	$-1,509,220,000	$-384,864,000	$-518,187,000
Total Unusual Items	$0	$1,089,136,000	$0	$137,704,000
Total Unusual Items Excluding Goodwill	$0	$1,089,136,000	$0	$137,704,000
Reconciled Depreciation	$5,177,000	$5,653,000	$6,623,000	$8,564,000
EBITDA (Bullshit earnings)	$-466,955,000	$-420,084,000	$-384,864,000	$-380,483,000
EBIT	$-472,132,000	$-425,737,000	$-391,487,000	$-389,047,000
Diluted Average Shares	$57,972,004	$57,889,255	$55,651,487	$54,789,435
Basic Average Shares	$57,972,004	$56,807,415	$55,651,487	$54,789,435
Diluted NI Availto Com Stockholders	$-412,781,000	$673,725,000	$-352,088,000	$-231,801,000
Tax Provision	$-1,016,000	$44,244,000	$0	$0
Gain On Sale Of Business	$0	$1,089,136,000	$0	$137,704,000
Research And Development	$339,535,000	$301,286,000	$295,526,000	$279,910,000
Selling General And Administration	$180,280,000	$156,784,000	$119,903,000	$121,673,000
Restructuring And Mergern Acquisition	-	-	-	$-127,853,000

Fetched: 2026-05-30

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$1,193,114,000	$1,540,956,000	$811,019,000	$1,100,814,000
Total Assets	$1,297,225,000	$1,663,199,000	$937,118,000	$1,238,718,000
Total Non Current Assets	$355,173,000	$697,599,000	$103,283,000	$405,946,000
Other Non Current Assets	$3,931,000	$4,724,000	$4,057,000	$3,956,000
Investmentin Financial Assets	$310,013,000	$638,321,000	$29,435,000	$313,874,000
Current Assets	$942,052,000	$965,600,000	$833,835,000	$832,772,000
Other Current Assets	$44,130,000	$40,165,000	$35,021,000	$38,955,000
Inventory	$32,920,000	$27,616,000	$19,076,000	$8,492,000
Receivables	$10,577,000	$4,109,000	$2,810,000	$2,206,000
Accounts Receivable	$10,577,000	$4,109,000	$2,810,000	$2,206,000
Cash Cash Equivalents And Short Term Investments	$854,425,000	$893,710,000	$776,928,000	$783,119,000
Cash And Cash Equivalents	$89,130,000	$76,247,000	$88,205,000	$139,259,000
Assets Held For Sale Current	-	-	-	-
Prepaid Assets	-	-	-	-
Other Receivables	-	-	-	-
Debt
Total Debt	$40,207,000	$56,988,000	$71,996,000	$85,659,000
Long Term Debt And Capital Lease Obligation	$21,815,000	$40,207,000	$56,988,000	$71,996,000
Current Debt And Capital Lease Obligation	$18,392,000	$16,781,000	$15,008,000	$13,663,000
Liabilities
Total Liabilities Net Minority Interest	$104,111,000	$122,243,000	$126,099,000	$137,904,000
Total Non Current Liabilities Net Minority Interest	$21,905,000	$41,087,000	$58,144,000	$75,275,000
Other Non Current Liabilities	$90,000	$880,000	$1,156,000	$3,279,000
Current Liabilities	$82,206,000	$81,156,000	$67,955,000	$62,629,000
Payables And Accrued Expenses	$36,550,000	$34,440,000	$29,715,000	$30,861,000
Payables	$18,355,000	$17,514,000	$9,780,000	$18,616,000
Total Tax Payable	$0	$871,000	$0	-
Income Tax Payable	$0	$871,000	$0	-
Accounts Payable	$18,355,000	$16,643,000	$9,780,000	$18,616,000
Liabilities Heldfor Sale Non Current	-	-	-	-
Equity
Common Stock Equity	$1,193,114,000	$1,540,956,000	$811,019,000	$1,100,814,000
Total Equity Gross Minority Interest	$1,193,114,000	$1,540,956,000	$811,019,000	$1,100,814,000
Stockholders Equity	$1,193,114,000	$1,540,956,000	$811,019,000	$1,100,814,000
Gains Losses Not Affecting Retained Earnings	$2,193,000	$-1,518,000	$-441,000	$-12,535,000
Other Equity Adjustments	$2,193,000	$-1,518,000	$-441,000	$-12,535,000
Retained Earnings	$-561,705,000	$-148,924,000	$-822,649,000	$-470,561,000
Other
Treasury Shares Number	$16,216,411	$16,216,411	$16,216,411	$16,216,411
Ordinary Shares Number	$58,448,592	$57,156,285	$55,945,078	$55,039,707
Share Issued	$74,665,003	$73,372,696	$72,161,489	$71,256,118
Tangible Book Value	$1,193,114,000	$1,540,956,000	$811,019,000	$1,100,814,000
Invested Capital	$1,193,114,000	$1,540,956,000	$811,019,000	$1,100,814,000
Working Capital	$859,846,000	$884,444,000	$765,880,000	$770,143,000
Capital Lease Obligations	$40,207,000	$56,988,000	$71,996,000	$85,659,000
Total Capitalization	$1,193,114,000	$1,540,956,000	$811,019,000	$1,100,814,000
Treasury Stock	$802,486,000	$802,486,000	$802,486,000	$802,486,000
Additional Paid In Capital	$2,555,037,000	$2,493,811,000	$2,436,523,000	$2,386,325,000
Capital Stock	$75,000	$73,000	$72,000	$71,000
Common Stock	$75,000	$73,000	$72,000	$71,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$21,815,000	$40,207,000	$56,988,000	$71,996,000
Current Capital Lease Obligation	$18,392,000	$16,781,000	$15,008,000	$13,663,000
Pensionand Other Post Retirement Benefit Plans Current	$27,264,000	$29,935,000	$23,232,000	$18,105,000
Current Accrued Expenses	$18,195,000	$16,926,000	$19,935,000	$12,245,000
Investments And Advances	$310,013,000	$638,321,000	$29,435,000	$313,874,000
Available For Sale Securities	$310,013,000	$638,321,000	$29,435,000	$313,874,000
Net PPE	$41,229,000	$54,554,000	$69,791,000	$88,116,000
Accumulated Depreciation	$-60,115,000	$-56,497,000	$-52,229,000	$-50,070,000
Gross PPE	$101,344,000	$111,051,000	$122,020,000	$138,186,000
Leases	$37,519,000	$37,519,000	$37,277,000	$37,277,000
Construction In Progress	$2,747,000	$897,000	$608,000	$657,000
Other Properties	$17,567,000	$17,529,000	$17,433,000	$23,182,000
Machinery Furniture Equipment	$13,057,000	$12,227,000	$12,293,000	$11,941,000
Buildings And Improvements	$30,454,000	$42,879,000	$54,409,000	$65,129,000
Properties	$0	$0	$0	$0
Finished Goods	$2,579,000	$3,018,000	$1,457,000	$942,000
Work In Process	$30,253,000	$24,509,000	$17,568,000	$7,550,000
Raw Materials	$88,000	$89,000	$51,000	$0
Other Short Term Investments	$765,295,000	$817,463,000	$688,723,000	$643,860,000

Fetched: 2026-05-30

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-387,293,000	$-391,526,000	$-314,561,000	$-314,359,000
Operating Activities
Operating Cash Flow	$-372,977,000	$-389,841,000	$-296,062,000	$-309,478,000
Cash Flow From Continuing Operating Activities	$-372,977,000	$-389,841,000	$-296,062,000	$-309,478,000
Operating Gains Losses	$-113,000	$-200,206,000	$525,000	$-48,000
Cash From Discontinued Operating Activities	-	-	$0	$0
Investing Activities
Capital Expenditure	$-14,316,000	$-1,685,000	$-18,499,000	$-4,881,000
Investing Cash Flow	$377,184,000	$363,441,000	$239,575,000	$243,261,000
Cash Flow From Continuing Investing Activities	$377,184,000	$363,441,000	$239,575,000	$243,261,000
Cash From Discontinued Investing Activities	-	-	$0	$0
Net Other Investing Changes	-	-	-	$131,784,000
Financing Activities
Financing Cash Flow	$8,676,000	$14,442,000	$5,433,000	$2,350,000
Cash Flow From Continuing Financing Activities	$8,676,000	$14,442,000	$5,433,000	$2,350,000
Repurchase Of Capital Stock	-	-	$0	$0
Net Common Stock Issuance	-	-	$0	$0
Cash From Discontinued Financing Activities	-	-	-	$0
Issuance Of Capital Stock	-	-	-	-
Common Stock Issuance	-	-	-	-
Other
Income Tax Paid Supplemental Data	$628,000	$43,150,000	$1,569,000	$0
End Cash Position	$89,130,000	$76,247,000	$88,205,000	$139,259,000
Beginning Cash Position	$76,247,000	$88,205,000	$139,259,000	$203,126,000
Changes In Cash	$12,883,000	$-11,958,000	$-51,054,000	$-63,867,000
Proceeds From Stock Option Exercised	$8,676,000	$14,442,000	$5,433,000	$2,681,000
Net Investment Purchase And Sale	$391,500,000	$-724,050,000	$256,749,000	$115,394,000
Sale Of Investment	$1,033,259,000	$818,383,000	$674,679,000	$1,146,175,000
Purchase Of Investment	$-641,759,000	$-1,542,433,000	$-417,930,000	$-1,030,781,000
Net Business Purchase And Sale	$0	$1,089,136,000	$0	$131,784,000
Sale Of Business	$0	$1,089,136,000	$0	$131,784,000
Net Intangibles Purchase And Sale	$-10,000,000	$0	$-17,500,000	$0
Purchase Of Intangibles	$-10,000,000	$0	$-17,500,000	$0
Net PPE Purchase And Sale	$-4,316,000	$-1,645,000	$326,000	$-3,917,000
Sale Of PPE	$0	$40,000	$1,325,000	$964,000
Purchase Of PPE	$-4,316,000	$-1,685,000	$-999,000	$-4,881,000
Change In Working Capital	$-33,042,000	$-19,768,000	$-19,057,000	$-16,433,000
Change In Other Current Liabilities	$-17,571,000	$-15,284,000	$-15,786,000	$-7,825,000
Change In Payables And Accrued Expense	$-527,000	$11,166,000	$4,084,000	$1,819,000
Change In Accrued Expense	$-1,402,000	$3,694,000	$12,817,000	$-1,617,000
Change In Payable	$875,000	$7,472,000	$-8,733,000	$3,436,000
Change In Account Payable	$1,746,000	$6,601,000	$-8,733,000	$3,436,000
Change In Tax Payable	$-871,000	$871,000	$0	$0
Change In Income Tax Payable	$-871,000	$871,000	$0	$0
Change In Prepaid Assets	$-3,172,000	$-5,811,000	$3,833,000	$-176,000
Change In Inventory	$-5,304,000	$-8,540,000	$-10,584,000	$-8,492,000
Change In Receivables	$-6,468,000	$-1,299,000	$-604,000	$-1,759,000
Changes In Account Receivables	$-6,468,000	$-1,299,000	$-604,000	$-2,206,000
Other Non Cash Items	$22,425,000	$-877,606,000	$28,220,000	$-117,858,000
Stock Based Compensation	$52,552,000	$42,847,000	$44,766,000	$49,296,000
Amortization Of Securities	$-7,195,000	$-14,486,000	$-5,051,000	$-1,198,000
Depreciation Amortization Depletion	$5,177,000	$5,653,000	$6,623,000	$8,564,000
Depreciation And Amortization	$5,177,000	$5,653,000	$6,623,000	$8,564,000
Gain Loss On Investment Securities	$-118,000	$-167,000	$-28,000	-
Gain Loss On Sale Of PPE	$5,000	$-39,000	$553,000	$-48,000
Gain Loss On Sale Of Business	$0	$-200,000,000	$0	$0
Net Income From Continuing Operations	$-412,781,000	$673,725,000	$-352,088,000	$-231,801,000
Repayment Of Debt	-	$0	$0	$-331,000
Net Issuance Payments Of Debt	-	$0	$0	$-331,000
Net Long Term Debt Issuance	-	$0	$0	$-331,000
Long Term Debt Payments	-	$0	$0	$-331,000
Common Stock Payments	-	-	$0	$0

Fetched: 2026-05-30